{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:45:48Z","timestamp":1790970348051,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T00:00:00Z","timestamp":1698451200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Lipids Health Dis"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Variations in the prevalence and systemic inflammatory (SI) status between non-alcoholic fatty liver disease (NAFLD) and newly defined metabolic dysfunction-associated fatty liver disease (MAFLD) have only been reported by few studies. Hence, this study aimed to compile data on the prevalence and the systemic inflammation levels of MAFLD and NAFLD in a general population from Southeast China was summarized to explore the potential effect of the transformation of disease definition.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A total of 6718 general population participants aged 35\u201375 were enrolled. Logistic regression and restricted cubic spline (RCS) models were used to examine the relationship between 15 SI indicators and NAFLD and MAFLD. The predicted values of MAFLD and NAFLD were analyzed using the receiver operating characteristic (ROC) curve.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The prevalence of MAFLD and NAFLD was 34.7% and 32.4%, respectively. Their overlapping rate was 89.7%, while only 8.3% and 1.9% of participants were MAFLD-only and NAFLD-only. Among three FLD groups, the MAFLD-only group had the highest levels of 8 SI indicators, including CRP, WBC, LYMPH, NEUT, MONO, ALB, NLR, and SIRI. The non-FLD group had the lower levels of all 15 SI indicators compared with all FLD subgroups. The odds ratios (ORs) of 10 SI indicators were significant in both multivariable-adjusted logistic regression and RCS analyses of MAFLD or NAFLD, including CRP, WBC, LYMPH, NEUT, MONO, ALB, PLR, LMR, ALI and CA. ROC analysis showed that the AUC values of all SI were lower than 0.7 in both MAFLD and NAFLD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>MAFLD could cover more FLD than NAFLD, and the MAFLD-only group had a more severe inflammation status, whereas the NAFLD-only exhibited lower levels. Moreover, there was not a high AUC and a high sensitivity of SI indicators, suggesting that SI indicators are not good indicators to diagnose NAFLD\/MAFLD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12944-023-01947-4","type":"journal-article","created":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T12:01:28Z","timestamp":1698494488000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Shift in prevalence and systemic inflammation levels from NAFLD to MAFLD: a population-based cross-sectional study"],"prefix":"10.1186","volume":"22","author":[{"given":"Qingdan","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meilan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyin","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruimei","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanxin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jun","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haiying","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenxin","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijian","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanshan","family":"Du","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weimin","family":"Ye","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,10,28]]},"reference":[{"key":"1947_CR1","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","volume":"4","author":"J Li","year":"2019","unstructured":"Li J, Zou B, Yeo YH, Feng Y, Xie X, Lee DH, et al. Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999\u20132019: a systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2019;4:389\u201398.","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"1947_CR2","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1002\/hep.28431","volume":"64","author":"ZM Younossi","year":"2016","unstructured":"Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73\u201384.","journal-title":"Hepatology"},{"key":"1947_CR3","doi-asserted-by":"publisher","first-page":"1038","DOI":"10.1111\/imj.14709","volume":"50","author":"TD Huang","year":"2020","unstructured":"Huang TD, Behary J, Zekry A. Non-alcoholic fatty liver disease: a review of epidemiology, risk factors, diagnosis and management. Intern Med J. 2020;50:1038\u201347.","journal-title":"Intern Med J"},{"key":"1947_CR4","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","volume":"158","author":"M Eslam","year":"2020","unstructured":"Eslam M, Sanyal AJ, George J, International Consensus P. MAFLD: a consensus-driven proposed nomenclature for metabolic associated fatty liver disease. Gastroenterology. 2020;158:1999\u20132014 (e1991).","journal-title":"Gastroenterology"},{"key":"1947_CR5","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1016\/j.metabol.2016.01.012","volume":"65","author":"Y Fazel","year":"2016","unstructured":"Fazel Y, Koenig AB, Sayiner M, Goodman ZD, Younossi ZM. Epidemiology and natural history of non-alcoholic fatty liver disease. Metabolism. 2016;65:1017\u201325.","journal-title":"Metabolism"},{"key":"1947_CR6","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1111\/liv.15139","volume":"42","author":"I Ayada","year":"2022","unstructured":"Ayada I, van Kleef LA, Alferink LJM, Li P, de Knegt RJ, Pan Q. Systematically comparing epidemiological and clinical features of MAFLD and NAFLD by meta-analysis: focusing on the non-overlap groups. Liver Int. 2022;42:277\u201387.","journal-title":"Liver Int"},{"key":"1947_CR7","unstructured":"Lim GEH, Tang A, Ng CH, Chin YH, Lim WH, Tan DJH, et al. An observational data meta-Analysis on the differences in prevalence and risk factors between MAFLD vs NAFLD. Clin Gastroenterol Hepatol. 2021."},{"key":"1947_CR8","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12986-021-00611-x","volume":"18","author":"J Fan","year":"2021","unstructured":"Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab (Lond). 2021;18:82.","journal-title":"Nutr Metab (Lond)"},{"key":"1947_CR9","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1186\/s12986-021-00611-x","volume":"18","author":"J Fan","year":"2021","unstructured":"Fan J, Luo S, Ye Y, Ju J, Zhang Z, Liu L, et al. Prevalence and risk factors of metabolic associated fatty liver disease in the contemporary South China population. Nutr Metab. 2021;18:82.","journal-title":"Nutr Metab"},{"key":"1947_CR10","first-page":"188","volume":"17","author":"H Li","year":"2020","unstructured":"Li H, Guo M, An Z, Meng J, Jiang J, Song J, et al. Prevalence and risk factors of metabolic associated fatty liver disease in Xinxiang, China. Int J Environ Res Public Health. 2020;17:188.","journal-title":"Int J Environ Res Public Health"},{"key":"1947_CR11","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1210\/clinem\/dgab641","volume":"107","author":"Y Liang","year":"2022","unstructured":"Liang Y, Chen H, Liu Y, Hou X, Wei L, Bao Y, et al. Association of MAFLD with diabetes, chronic kidney disease, and cardiovascular disease: a 4.6-year cohort study in China. J Clin Endocrinol Metab. 2022;107:88\u201397.","journal-title":"J Clin Endocrinol Metab"},{"key":"1947_CR12","doi-asserted-by":"publisher","first-page":"e745","DOI":"10.1210\/clinem\/dgab644","volume":"107","author":"X Wang","year":"2022","unstructured":"Wang X, Wu S, Yuan X, Chen S, Fu Q, Sun Y, et al. Metabolic dysfunction-associated fatty liver disease and mortality among Chinese adults: a prospective cohort study. J Clin Endocrinol Metab. 2022;107:e745-755.","journal-title":"J Clin Endocrinol Metab"},{"key":"1947_CR13","doi-asserted-by":"publisher","first-page":"6","DOI":"10.14218\/JCTH.2021.00089","volume":"10","author":"C Yu","year":"2022","unstructured":"Yu C, Wang M, Zheng S, Xia M, Yang H, Zhang D, et al. Comparing the diagnostic criteria of MAFLD and NAFLD in the Chinese Population: a Population-based prospective cohort study. J Clin Transl Hepatol. 2022;10:6\u201316.","journal-title":"J Clin Transl Hepatol"},{"key":"1947_CR14","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.hbpd.2022.01.006","volume":"21","author":"J Zeng","year":"2022","unstructured":"Zeng J, Qin L, Jin Q, Yang RX, Ning G, Su Q, et al. Prevalence and characteristics of MAFLD in Chinese adults aged 40 years or older: a community-based study. Hepatobiliary Pancreat Dis Int. 2022;21:154\u201361.","journal-title":"Hepatobiliary Pancreat Dis Int"},{"key":"1947_CR15","doi-asserted-by":"publisher","first-page":"1095","DOI":"10.1002\/hep.30848","volume":"70","author":"HW Lee","year":"2019","unstructured":"Lee HW, Wong VW. Changing NAFLD epidemiology in China. Hepatology. 2019;70:1095\u20138.","journal-title":"Hepatology"},{"key":"1947_CR16","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1007\/s12072-020-10023-3","volume":"14","author":"Y Wu","year":"2020","unstructured":"Wu Y, Zheng Q, Zou B, Yeo YH, Li X, Li J, et al. The epidemiology of NAFLD in Mainland China with analysis by adjusted gross regional domestic product: a meta-analysis. Hepatol Int. 2020;14:259\u201369.","journal-title":"Hepatol Int"},{"key":"1947_CR17","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/hep.31150","volume":"71","author":"J Zhou","year":"2020","unstructured":"Zhou J, Zhou F, Wang W, Zhang XJ, Ji YX, Zhang P, et al. Epidemiological features of NAFLD from 1999 to 2018 in China. Hepatology. 2020;71:1851\u201364.","journal-title":"Hepatology"},{"key":"1947_CR18","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1172\/JCI88881","volume":"127","author":"Y Koyama","year":"2017","unstructured":"Koyama Y, Brenner DA. Liver inflammation and fibrosis. J Clin Invest. 2017;127:55\u201364.","journal-title":"J Clin Invest"},{"key":"1947_CR19","doi-asserted-by":"publisher","first-page":"830","DOI":"10.1136\/gutjnl-2014-306842","volume":"64","author":"YA Lee","year":"2015","unstructured":"Lee YA, Wallace MC, Friedman SL. Pathobiology of liver fibrosis: a translational success story. Gut. 2015;64:830\u201341.","journal-title":"Gut"},{"key":"1947_CR20","doi-asserted-by":"publisher","first-page":"107609","DOI":"10.1016\/j.intimp.2021.107609","volume":"97","author":"S Chen","year":"2021","unstructured":"Chen S, Guo H, Xie M, Zhou C, Zheng M. Neutrophil: an emerging player in the occurrence and progression of metabolic associated fatty liver disease. Int Immunopharmacol. 2021;97:107609.","journal-title":"Int Immunopharmacol"},{"key":"1947_CR21","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1053\/j.gastro.2016.01.025","volume":"150","author":"B Gao","year":"2016","unstructured":"Gao B, Tsukamoto H. Inflammation in alcoholic and nonalcoholic fatty liver disease: friend or foe? Gastroenterology. 2016;150:1704\u20139.","journal-title":"Gastroenterology"},{"key":"1947_CR22","doi-asserted-by":"publisher","first-page":"349","DOI":"10.1038\/s41575-018-0009-6","volume":"15","author":"S Schuster","year":"2018","unstructured":"Schuster S, Cabrera D, Arrese M, Feldstein AE. Triggering and resolution of inflammation in NASH. Nat Rev Gastroenterol Hepatol. 2018;15:349\u201364.","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"1947_CR23","doi-asserted-by":"publisher","first-page":"781567","DOI":"10.3389\/fmed.2021.781567","volume":"8","author":"P Torre","year":"2021","unstructured":"Torre P, Motta BM, Sciorio R, Masarone M, Persico M. Inflammation and fibrogenesis in MAFLD: role of the hepatic immune system. Front Med (Lausanne). 2021;8:781567.","journal-title":"Front Med (Lausanne)"},{"key":"1947_CR24","doi-asserted-by":"publisher","first-page":"746747","DOI":"10.3389\/fendo.2021.746747","volume":"12","author":"SY Lin","year":"2021","unstructured":"Lin SY, Li WC, Yang TA, Chen YC, Yu W, Huang HY, et al. Optimal threshold of homeostasis model assessment of insulin resistance to identify metabolic syndrome in a Chinese population aged 45 years or younger. Front Endocrinol (Lausanne). 2021;12:746747.","journal-title":"Front Endocrinol (Lausanne)"},{"key":"1947_CR25","first-page":"283","volume":"8","author":"F Schaffner","year":"1986","unstructured":"Schaffner F, Thaler H. Nonalcoholic fatty liver disease. Prog Liver Dis. 1986;8:283\u201398.","journal-title":"Prog Liver Dis"},{"key":"1947_CR26","first-page":"182","volume":"16","author":"Joint Committee for Guideline R","year":"2019","unstructured":"Joint Committee for Guideline R. 2018 Chinese guidelines for prevention and treatment of hypertension-A report of the revision committee of Chinese Guidelines for prevention and treatment of hypertension. J Geriatr Cardiol. 2019;16:182\u2013241.","journal-title":"J Geriatr Cardiol"},{"key":"1947_CR27","doi-asserted-by":"publisher","first-page":"S17","DOI":"10.2337\/dc22-S002","volume":"45","author":"American Diabetes Association Professional Practice C","year":"2022","unstructured":"American Diabetes Association Professional Practice C. 2. Classification and diagnosis of Diabetes: standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45:17\u2013S38.","journal-title":"Diabetes Care"},{"key":"1947_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2020.106504","volume":"84","author":"AP Yang","year":"2020","unstructured":"Yang AP, Liu JP, Tao WQ, Li HM. The diagnostic and predictive role of NLR, d-NLR and PLR in COVID-19 patients. Int Immunopharmacol. 2020;84:106504.","journal-title":"Int Immunopharmacol"},{"key":"1947_CR29","doi-asserted-by":"publisher","first-page":"e22964","DOI":"10.1002\/jcla.22964","volume":"33","author":"J Liu","year":"2019","unstructured":"Liu J, Li S, Zhang S, Liu Y, Ma L, Zhu J, et al. Systemic immune-inflammation index, neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio can predict clinical outcomes in patients with metastatic non-small-cell Lung cancer treated with nivolumab. J Clin Lab Anal. 2019;33:e22964.","journal-title":"J Clin Lab Anal"},{"key":"1947_CR30","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1245\/s10434-014-4048-0","volume":"22","author":"A Kinoshita","year":"2014","unstructured":"Kinoshita A, Onoda H, Imai N, Iwaku A, Oishi M, Tanaka K, et al. The C-reactive protein\/albumin ratio, a novel inflammation-based prognostic score, predicts outcomes in patients with hepatocellular carcinoma. Ann Surg Oncol. 2014;22:803\u201310.","journal-title":"Ann Surg Oncol"},{"key":"1947_CR31","doi-asserted-by":"publisher","first-page":"886","DOI":"10.21037\/tlcr.2019.11.16","volume":"8","author":"H Mandaliya","year":"2019","unstructured":"Mandaliya H, Jones M, Oldmeadow C, Nordman II. Prognostic biomarkers in stage IV non-small cell lung cancer (NSCLC): neutrophil to lymphocyte ratio (NLR), lymphocyte to monocyte ratio (LMR), platelet to lymphocyte ratio (PLR) and advanced lung cancer inflammation index (ALI). Transl Lung Cancer Res. 2019;8:886\u201394.","journal-title":"Transl Lung Cancer Res"},{"key":"1947_CR32","doi-asserted-by":"publisher","first-page":"3919","DOI":"10.1007\/s10067-021-05762-z","volume":"40","author":"Z Jin","year":"2021","unstructured":"Jin Z, Hao D, Song Y, Zhuang L, Wang Q, Yu X. Systemic inflammatory response index as an Independent risk factor for ischemic stroke in patients with rheumatoid arthritis: a retrospective study based on propensity score matching. Clin Rheumatol. 2021;40:3919\u201327.","journal-title":"Clin Rheumatol"},{"key":"1947_CR33","doi-asserted-by":"publisher","first-page":"17932","DOI":"10.3748\/wjg.v20.i47.17932","volume":"20","author":"RN Feng","year":"2014","unstructured":"Feng RN, Du SS, Wang C, Li YC, Liu LY, Guo FC, et al. Lean-non-alcoholic fatty liver disease increases risk for metabolic disorders in a normal weight Chinese population. World J Gastroenterol. 2014;20:17932\u201340.","journal-title":"World J Gastroenterol"},{"key":"1947_CR34","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","volume":"73","author":"M Eslam","year":"2020","unstructured":"Eslam M, Newsome PN, Sarin SK, Anstee QM, Targher G, Romero-Gomez M, et al. A new definition for metabolic dysfunction-associated fatty liver disease: an international expert consensus statement. J Hepatol. 2020;73:202\u20139.","journal-title":"J Hepatol"},{"key":"1947_CR35","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1016\/j.cgh.2020.10.046","volume":"19","author":"VW Wong","year":"2021","unstructured":"Wong VW, Wong GL, Woo J, Abrigo JM, Chan CK, Shu SS, et al. Impact of the new definition of metabolic associated fatty liver disease on the epidemiology of the disease. Clin Gastroenterol Hepatol. 2021;19:2161-2171 e2165.","journal-title":"Clin Gastroenterol Hepatol"},{"key":"1947_CR36","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1111\/hepr.13685","volume":"51","author":"T Tsutsumi","year":"2021","unstructured":"Tsutsumi T, Eslam M, Kawaguchi T, Yamamura S, Kawaguchi A, Nakano D, et al. MAFLD better predicts the progression of atherosclerotic cardiovascular risk than NAFLD: generalized estimating equation approach. Hepatol Res. 2021;51:1115\u201328.","journal-title":"Hepatol Res"},{"key":"1947_CR37","doi-asserted-by":"crossref","unstructured":"Chun HS, Lee M, Lee JS, Lee HW, Kim BK, Park JY, et al. Metabolic dysfunction associated fatty liver disease identifies subjects with cardiovascular risk better than non-alcoholic fatty liver disease. Liver Int. 2023;43(3):608\u201325.","DOI":"10.1111\/liv.15508"},{"key":"1947_CR38","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.jhep.2022.06.012","volume":"77","author":"M Peiseler","year":"2022","unstructured":"Peiseler M, Schwabe R, Hampe J, Kubes P, Heikenw\u00e4lder M, Tacke F. Immune mechanisms linking metabolic injury to inflammation and fibrosis in fatty liver disease \u2013 novel insights into cellular communication circuits. J Hepatol. 2022;77:1136\u201360.","journal-title":"J Hepatol"},{"key":"1947_CR39","doi-asserted-by":"publisher","first-page":"730","DOI":"10.3390\/cancers13040730","volume":"13","author":"M Peiseler","year":"2021","unstructured":"Peiseler M, Tacke F. Inflammatory mechanisms underlying nonalcoholic steatohepatitis and the transition to hepatocellular carcinoma. Cancers. 2021;13:730.","journal-title":"Cancers"},{"issue":"2","key":"1947_CR40","doi-asserted-by":"publisher","first-page":"419","DOI":"10.3390\/life13020419","volume":"13","author":"A Olveira","year":"2023","unstructured":"Olveira A, Augustin S, Benlloch S, Ampuero J, Su\u00e1rez-P\u00e9rez JA, Armesto S, et al. The essential role of IL-17 as the pathogenetic link between psoriasis and metabolic-associated fatty liver disease. Life. 2023;13(2):419.","journal-title":"Life"},{"key":"1947_CR41","doi-asserted-by":"publisher","first-page":"1836","DOI":"10.1002\/hep.24001","volume":"52","author":"H Tilg","year":"2010","unstructured":"Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010;52:1836\u201346.","journal-title":"Hepatology"},{"key":"1947_CR42","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1186\/s13098-022-00887-w","volume":"14","author":"T Tsutsumi","year":"2022","unstructured":"Tsutsumi T, Nakano D, Kawaguchi M, Hashida R, Yoshinaga S, Takahashi H, et al. MAFLD associated with COPD via systemic inflammation Independent of aging and smoking in men. Diabetol Metab Syndr. 2022;14:14.","journal-title":"Diabetol Metab Syndr"},{"key":"1947_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.880298","volume":"13","author":"Y Duan","year":"2022","unstructured":"Duan Y, Pan X, Luo J, Xiao X, Li J, Bestman PL, et al. Association of inflammatory cytokines with non-alcoholic fatty liver disease. Front Immunol. 2022;13: 880298.","journal-title":"Front Immunol"},{"key":"1947_CR44","doi-asserted-by":"publisher","first-page":"2233","DOI":"10.1007\/s40618-022-01848-w","volume":"45","author":"C Tong","year":"2022","unstructured":"Tong C, Li Q, Kong L, Ni X, Halengbieke A, Zhang S, et al. Sex-specific metabolic risk factors and their trajectories towards the non-alcoholic fatty Liver Disease incidence. J Endocrinol Invest. 2022;45:2233\u201345.","journal-title":"J Endocrinol Invest"},{"key":"1947_CR45","doi-asserted-by":"publisher","first-page":"100726","DOI":"10.1016\/j.aohep.2022.100726","volume":"28","author":"D Zhao","year":"2022","unstructured":"Zhao D, Cui H, Shao Z, Cao L. Abdominal obesity, chronic inflammation and the risk of non-alcoholic fatty liver disease. Ann Hepatol. 2022;28:100726.","journal-title":"Ann Hepatol"},{"key":"1947_CR46","doi-asserted-by":"publisher","first-page":"981196","DOI":"10.3389\/fendo.2022.981196","volume":"13","author":"Y Zhao","year":"2022","unstructured":"Zhao Y, Xia J, He H, Liang S, Zhang H, Gan W. Diagnostic performance of novel inflammatory biomarkers based on ratios of laboratory indicators for nonalcoholic fatty liver disease. Front Endocrinol (Lausanne). 2022;13:981196.","journal-title":"Front Endocrinol (Lausanne)"}],"container-title":["Lipids in Health and Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01947-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12944-023-01947-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12944-023-01947-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,28]],"date-time":"2023-10-28T13:02:15Z","timestamp":1698498135000},"score":1,"resource":{"primary":{"URL":"https:\/\/lipidworld.biomedcentral.com\/articles\/10.1186\/s12944-023-01947-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,28]]},"references-count":46,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1947"],"URL":"https:\/\/doi.org\/10.1186\/s12944-023-01947-4","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-3231080\/v1","asserted-by":"object"}]},"ISSN":["1476-511X"],"issn-type":[{"value":"1476-511X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,28]]},"assertion":[{"value":"3 August 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the ethical committee of the Fujian Medical University (approval number: 2020\u201358), and written informed consent was obtained from all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"185"}}